ArticleWorld journal of gastroenterology2010
Effects of four Bifidobacteria on obesity in high-fat diet induced rats.
Article in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence.Advances in nutrition (Bethesda, Md.) · 2024Pooled it
- Systematic review of probiotics as an adjuvant treatment for psychiatric disorders.Frontiers in behavioral neuroscience · 2023Pooled it
- Effects of probiotics on selected anthropometrics and biochemical measures in overweight or obese Saudi subjects: a double-blind, placebo-controlled, randomised clinical trial.Public health nutrition · 2024Trial
- The Consumption of a Synbiotic Does Not Affect the Immune, Inflammatory, and Sympathovagal Parameters in Athletes and Sedentary Individuals: A Triple-Blinded, Randomized, Place-bo-Controlled Pilot Study.International journal of environmental research and public health · 2022Trial
- Efficacy and Safety ofFrontiers in endocrinology · 2021Trial
- Trial
- Immune dysregulation and gut microbiota: Connection to health and disease development.Neural regeneration research · 2026Article
- Gut Microbiome in Obesity: A Narrative Review of Mechanisms, Interventions, and Future Directions.Probiotics and antimicrobial proteins · 2026Review
- Urolithin A: a multi-target therapeutic candidate derived from the gut microbiota for obesity and metabolic dysfunction.Frontiers in endocrinology · 2026Review
- Variation in Intramuscular Fat Deposition of Goats and Sheep and Its Correlation with Gut Microbiota.Foods (Basel, Switzerland) · 2025Article
- Orlistat ameliorates lipid dysmetabolism in high-fat diet-induced mice via gut microbiota modulation.Frontiers in microbiology · 2025Article
- Modulating Metabolic Health and Physiological Functions: Advances in Dietary Interventions Targeting Gut Microbiota.Therapeutics and clinical risk management · 2025Review
- Article
- Article
- Association between Gut Microbiota and Metabolic Health and Obesity Status in Cats.Animals : an open access journal from MDPI · 2024Article
- The Effect of Type 2 Resistant Starch and Indole-3-Propionic Acid on Ameliorating High-Fat-Diet-Induced Hepatic Steatosis and Gut Dysbiosis.Foods (Basel, Switzerland) · 2024Article
- Insights into the Anti-Adipogenic and Anti-Inflammatory Potentialities of Probiotics against Obesity.Nutrients · 2024Review
- Gut microbiome-metabolome interactions predict host condition.Microbiome · 2024Article
- Resveratrol impacts on aquatic animals: a review.Fish physiology and biochemistry · 2024Review
- Ameliorating Effects ofNutrients · 2023Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo compare the effects of four Bifidobacteria strains (Bifidobacteria L66-5, L75-4, M13-4 and FS31-12, originated from normal human intestines) on weight gain, lipid metabolism, glucose metabolism in an obese murine model induced by high-fat diet.
methodsForty-eight Sprague-Dawley rats were randomly divided into six groups. Control group received standard chow, model group received high-fat diet, and intervention groups received high-fat diet added with different Bifidobacteria strains isolated from healthy volunteers' fresh feces. All rats were executed at the 6th weekend. Body weight (BW), obese indexes, oral glucose tolerance test, serum and liver lipid and serum insulin (INS) were tested. Liver lipid deposition was classified pathologically.
resultsCompared with the model group, B. M13-4 improved BW gains (264.27 +/- 26.91 vs 212.55 +/- 18.54, P = 0.001) while B. L66-5 induced a decrease in BW (188.47 +/- 11.96 vs 212.55 +/- 18.54, P = 0.043). The rest two strains had no significant change in BW. All the four strains can reduce serum and liver triglyceride and significantly alleviate the lipid deposition in liver. All strains showed a trend of lowing serum and liver total cholesterol while B. L66-5 and B. FS31-12 did so more significantly. In addition, all the four strains showed no significant differences in serum INS and glucose level.
conclusionThe response of energy metabolism to administration of Bifidobacteria is strain dependent. Different strains of Bifidobacteria might drive different directions of fat distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.